Where is the live CopyMark page for USPTO serial 79150879?

The live record is at https://getcopymark.com/trademark/79150879. Use https://getcopymark.com/trademark/{serialNumber} for any 8-digit USPTO serial.

Who owns Serial No. 79150879?

According to the public USPTO record for serial number 79150879, the listed owner(s) include: CHONGQING QINGYANG PHARMACY CO., LTD., CHONGQING QINGYANG PHARMACY CO., LTD., CHONGQING QINGYANG PHARMACY CO., LTD..

What is USPTO serial number 79150879?

Serial number 79150879 is the USPTO application identifier for the mark Serial No. 79150879. It is used to track examination, publication, and registration of this trademark.

What is the current status of Serial No. 79150879?

Serial No. 79150879 (79150879) currently shows USPTO status code 404 on the public record. This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Which trademark classes cover Serial No. 79150879?

The public record lists International Classes: 005. Each class corresponds to categories of goods or services identified in the application or registration.

Trademark: Serial No. 79150879 Serial# 79150879 | status 404; last event DETH | Trademark Info & Attorney Guidance

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with Serial No. 79150879?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner

Monitor this mark, or talk with CopyMark about this registration.

Trademark Monitoring

(312) 319-4460

Not the owner?

File a new U.S. trademark application, or speak with our attorneys.

Start a new application

(312) 319-4460

Owner

Goods and services

Class	Description	Status	First use
005	Bulk pharmaceutical chemicals for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; medicines for human purposes for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; medicinal tonics for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; biological preparations for medical purposes for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; vitamin preparations; dietetic substances adapted for medical use, namely, dietetic sugar substitutes for medical use; Chemical preparations for pharmaceutical purposes for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders	SECTION 71 - CANCELLED	—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Date	Code	Event	What it means
Oct 26, 2024	DETH	DEATH OF INTERNATIONAL REGISTRATION	—
Jan 23, 2023	INNT	TOTAL INVALIDATION PROCESSED BY THE IB	—
Dec 14, 2022	XXSS	GENERIC MADRID TRANSACTION SENT TO IB	—
Dec 14, 2022	XXCR	GENERIC MADRID TRANSACTION CREATED	—
Nov 25, 2022	INTR	TOTAL INVALIDATION OF REG EXT PROTECTION CREATED	—
Mar 25, 2022	C71T	CANCELLED SECTION 71	—
Oct 20, 2017	ADCH	CHANGE OF NAME/ADDRESS REC'D FROM IB	—
Jul 22, 2016	FINO	FINAL DECISION TRANSACTION PROCESSED BY IB	—
Mar 24, 2016	XXSS	GENERIC MADRID TRANSACTION SENT TO IB	—
Mar 24, 2016	XXCR	GENERIC MADRID TRANSACTION CREATED	—
Dec 8, 2015	FICR	FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB	—
Sep 8, 2015	R.PR	REGISTERED-PRINCIPAL REGISTER	Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jun 23, 2015	PUBO	PUBLISHED FOR OPPOSITION	Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jun 3, 2015	NPUB	NOTICE OF PUBLICATION	—
May 7, 2015	DMCC	DATA MODIFICATION COMPLETED	—
Apr 7, 2015	PBCR	WITHDRAWN FROM PUB - OG REVIEW QUERY	—
Mar 10, 2015	PBCR	WITHDRAWN FROM PUB - OG REVIEW QUERY	—
Feb 24, 2015	PREV	LAW OFFICE PUBLICATION REVIEW COMPLETED	—
Feb 13, 2015	ALIE	ASSIGNED TO LIE	—
Jan 27, 2015	CNSA	APPROVED FOR PUB - PRINCIPAL REGISTER	—
Jan 8, 2015	TEME	TEAS/EMAIL CORRESPONDENCE ENTERED	—
Jan 7, 2015	CRFA	CORRESPONDENCE RECEIVED IN LAW OFFICE	—
Jan 7, 2015	TROA	TEAS RESPONSE TO OFFICE ACTION RECEIVED	This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Nov 17, 2014	CNRT	NON-FINAL ACTION MAILED	A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 14, 2014	CNRT	NON-FINAL ACTION WRITTEN	A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Oct 24, 2014	TEME	TEAS/EMAIL CORRESPONDENCE ENTERED	—
Oct 24, 2014	CRFA	CORRESPONDENCE RECEIVED IN LAW OFFICE	—
Oct 24, 2014	TROA	TEAS RESPONSE TO OFFICE ACTION RECEIVED	This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Oct 24, 2014	TROA	TEAS RESPONSE TO OFFICE ACTION RECEIVED	This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 19, 2014	RFNT	REFUSAL PROCESSED BY IB	—
Sep 4, 2014	RFCS	NON-FINAL ACTION MAILED - REFUSAL SENT TO IB	—
Sep 4, 2014	RFRR	REFUSAL PROCESSED BY MPU	—
Sep 1, 2014	RFCR	NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW	—
Aug 31, 2014	CNRT	NON-FINAL ACTION WRITTEN	A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 26, 2014	MAFR	APPLICATION FILING RECEIPT MAILED	—
Aug 22, 2014	DOCK	ASSIGNED TO EXAMINER	—
Aug 22, 2014	NWOS	NEW APPLICATION OFFICE SUPPLIED DATA ENTERED	—
Aug 21, 2014	REPR	SN ASSIGNED FOR SECT 66A APPL FROM IB	—

Serial No. 79150879